Loading…
Identification of Oligomerization and Drug-binding Domains of the Membrane Fusion Protein EmrA
Many pathogenic Gram-negative bacteria possess tripartite transporters that catalyze drug extrusion across the inner and outer membranes, thereby conferring resistance. These transporters consist of inner (IMP) and outer (OMP) membrane proteins, which are coupled by a periplasmic membrane fusion (MF...
Saved in:
Published in: | The Journal of biological chemistry 2003-04, Vol.278 (15), p.12903-12912 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Many pathogenic Gram-negative bacteria possess tripartite transporters that catalyze drug extrusion across the inner and outer
membranes, thereby conferring resistance. These transporters consist of inner (IMP) and outer (OMP) membrane proteins, which
are coupled by a periplasmic membrane fusion (MFP) protein. However, it is not know whether the MFP translocates the drug
between the membranes, by acting as a channel, or whether it brings the IMP and OMP together, facilitating drug transfer.
The MFP EmrA has an elongated periplasmic domain, which binds transported drugs, and is anchored to the inner membrane by
a single α-helix, which contains a leucine zipper dimerization domain. Consistent with CD and hydrodynamic analyses, the periplasmic
domain is predicted to be composed of a β-sheet subdomain and an α-helical coiled-coil. We propose that EmrA forms a trimer
in which the coiled-coils radiate across the periplasm, where they could sequester the OMP TolC. The âfreeâ leucine zipper
in the EmrA trimer might stabilize the interaction with the IMP EmrB, which also possesses leucine zipper motifs in the putative
N- and C-terminal helices. The β-sheet subdomain of EmrA would sit at the membrane surface adjacent to the EmrB, from which
it receives the transported drug, inducing a conformational change that triggers the interaction with the OMP. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M209457200 |